

## Product datasheet for **TA384673**

### LOXL2 Rabbit Monoclonal Antibody [Clone ID: R09-7J5]

#### Product data:

Product Type:	Primary Antibodies
Clone Name:	R09-7J5
Applications:	WB
Recommended Dilution:	WB: 1/1000
Reactivity:	Human
Host:	Rabbit
Isotype:	IgG
Clonality:	Monoclonal
Immunogen:	A synthetic peptide of human LOXL2
Formulation:	50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA
Concentration:	lot specific
Purification:	Affinity Purified
Conjugation:	Unconjugated
Storage:	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Stability:	1 year
Predicted Protein Size:	Calculated MW: 87 kDa; Observed MW: 105 kDa
Gene Name:	lysyl oxidase like 2
Database Link:	<a href="#">Entrez Gene 4017 Human Q9Y4K0</a>



[View online »](#)


**Background:**

Swiss-Prot Acc.Q9Y4K0. Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine) (PubMed:27735137). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation (PubMed:27735137). Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2) (PubMed:27735137). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription (PubMed:25959397). LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3 (PubMed:16096638, PubMed:27735137, PubMed:24414204). During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription (PubMed:24239292). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (PubMed:24239292). Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction (PubMed:28332555). Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression (PubMed:20026874). When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin (PubMed:20306300). Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding (PubMed:21835952). Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.

**Synonyms:**

LOR2; WS9-14

## Product images:



Western blot analysis of LOXL2 in U87-MG lysates using LOXL2 antibody.